Total IgG levels were determined in serum samples pretreatment and again 2 weeks after treatment. Some patients also had IgG levels measured at 4 weeks (91 patients), 3 months (86 patients), and 6 ...

This pilot clinical trial evaluated safety and tolerability of intravenous immunoglobulin ... comparing pre- to post-treatment. Conclusions Treatment with IVIG appears to be safe, feasible ...

Physicians currently treat pregnancies at risk of FNAIT with intravenous immunoglobulin with or without steroids. FREESIA-3 is a phase 3, multicenter, randomized, open-label trial of nipocalimab or ...

Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...

Guillain-Barré Syndrome occurs when the body’s immune system mistakenly attacks nerve cells, disrupting communication between ...

HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...

A 37-year-old driver from Pune, diagnosed with Guillain-Barre Syndrome (GBS), has succumbed to the rare nerve disorder, ...

Parents of children diagnosed with Guillain-Barré Syndrome (GBS) at Kashibai Navale Hospital and Medical College (KNHMC) have ...

Early diagnosis and treatment can significantly reduce morbidity and mortality, help to limit disability and improve outcomes ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Study participants who went on an IgG-based elimination diet--based on a novel blood test--experienced less abdominal pain than those on a sham diet.